Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Scientists discovered two genes involved in hyperemesis gravidarum, a condition that can cause extreme nausea and vomiting ...

While most students spend their January break catching up on well-deserved sleep or binge-watching Netflix, 20-year-old Ruby ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...

Sanofi and Regeneron’s once close relationship has ... refocus Sanofi since taking the helm – for example axing R&D in diabetes, once its cash-cow category, and cardiovascular – in order ...

AZ and Regeneron will collaborate on finding small ... which puts the programme firmly in AZ's wheelhouse given its focus on diabetes with drugs like its blockbuster SGLT2 inhibitor Farxiga ...

Biocon Biologics Ltd, a subsidiary of Biocon Limited, announced a major achievement through a settlement and license agreement with Regeneron to launch Yesafili in the US market as an interchangeable ...

BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...

Burdened by continuing troublesome inflation and cuts to federal health agencies, health care sector stocks are barely treading water. The S&P 500 Health Care Sector Index was fla ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.